Private equity firm Hony Capital divested an 11% stake in CSPC Pharmaceutical after Thursday's close in Hong Kong, raising HK$4.095 billion US$528 million from the sale of 650 million secondary shares.
Under the lead management of Goldman Sachs, Morgan Stanley and UBS, the group priced the accelerated block at HK$6.30 per share. This represented the very bottom end of a HK$6.30 to HK$6.45 range and an 8.3% discount to the stock's HK$6.87 close.
The order book was said to have closed just over two times covered, with participation from roughly 100 accounts. In terms of allocations, the top 10 investors...
¬ Haymarket Media Limited. All rights reserved.
